WO2018078067A1 - Aerosol spray containing viable bacterial species - Google Patents
Aerosol spray containing viable bacterial species Download PDFInfo
- Publication number
- WO2018078067A1 WO2018078067A1 PCT/EP2017/077547 EP2017077547W WO2018078067A1 WO 2018078067 A1 WO2018078067 A1 WO 2018078067A1 EP 2017077547 W EP2017077547 W EP 2017077547W WO 2018078067 A1 WO2018078067 A1 WO 2018078067A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aerosol spray
- anyone
- spray according
- propellant
- siloxanes
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 84
- 239000007921 spray Substances 0.000 title claims abstract description 72
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 claims description 87
- 241000894006 Bacteria Species 0.000 claims description 56
- -1 siloxanes Chemical class 0.000 claims description 50
- 239000003380 propellant Substances 0.000 claims description 48
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 38
- 239000006041 probiotic Substances 0.000 claims description 29
- 235000018291 probiotics Nutrition 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 28
- 238000004062 sedimentation Methods 0.000 claims description 22
- 239000000725 suspension Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 20
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 20
- 239000004310 lactic acid Substances 0.000 claims description 19
- 235000014655 lactic acid Nutrition 0.000 claims description 19
- 239000003006 anti-agglomeration agent Substances 0.000 claims description 17
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 17
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 16
- 230000000529 probiotic effect Effects 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 229940086555 cyclomethicone Drugs 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 10
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 8
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 8
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 7
- 229930195733 hydrocarbon Natural products 0.000 claims description 7
- 150000002430 hydrocarbons Chemical class 0.000 claims description 7
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 241000736262 Microbiota Species 0.000 claims description 6
- 230000036074 healthy skin Effects 0.000 claims description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 6
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 claims description 6
- 239000001273 butane Substances 0.000 claims description 5
- 239000003974 emollient agent Substances 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000001294 propane Substances 0.000 claims description 4
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims description 3
- 239000004909 Moisturizer Substances 0.000 claims description 3
- 239000000440 bentonite Substances 0.000 claims description 3
- 229910000278 bentonite Inorganic materials 0.000 claims description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 3
- 229910021485 fumed silica Inorganic materials 0.000 claims description 3
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 claims description 3
- 229910000271 hectorite Inorganic materials 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 229920000592 inorganic polymer Polymers 0.000 claims description 3
- 230000001333 moisturizer Effects 0.000 claims description 3
- 239000002304 perfume Substances 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 abstract description 11
- 238000009472 formulation Methods 0.000 description 45
- 229920001296 polysiloxane Polymers 0.000 description 43
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 18
- 229910052710 silicon Inorganic materials 0.000 description 18
- 239000010703 silicon Substances 0.000 description 18
- 241000894007 species Species 0.000 description 18
- 230000035899 viability Effects 0.000 description 18
- 239000012530 fluid Substances 0.000 description 17
- 238000003860 storage Methods 0.000 description 17
- 239000007788 liquid Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 239000004205 dimethyl polysiloxane Substances 0.000 description 14
- 239000007789 gas Substances 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 13
- 230000007774 longterm Effects 0.000 description 12
- 239000003921 oil Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 240000006024 Lactobacillus plantarum Species 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 241000186660 Lactobacillus Species 0.000 description 6
- 229940008099 dimethicone Drugs 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000001166 anti-perspirative effect Effects 0.000 description 5
- 239000003213 antiperspirant Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000009834 vaporization Methods 0.000 description 5
- 230000008016 vaporization Effects 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229960004424 carbon dioxide Drugs 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 125000002496 methyl group Chemical class [H]C([H])([H])* 0.000 description 3
- 230000002906 microbiologic effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000001272 nitrous oxide Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 229920002050 silicone resin Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 1
- RWNUSVWFHDHRCJ-UHFFFAOYSA-N 1-butoxypropan-2-ol Chemical compound CCCCOCC(C)O RWNUSVWFHDHRCJ-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- ZPQAUEDTKNBRNG-UHFFFAOYSA-N 2-methylprop-2-enoylsilicon Chemical compound CC(=C)C([Si])=O ZPQAUEDTKNBRNG-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- AFUWHLXUBJOPNO-UHFFFAOYSA-N CCCCCCCCCCCCCCCC[SiH3] Chemical compound CCCCCCCCCCCCCCCC[SiH3] AFUWHLXUBJOPNO-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000186684 Lactobacillus pentosus Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229910002808 Si–O–Si Inorganic materials 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001998 anti-microbiological effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002199 base oil Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940102552 disteardimonium hectorite Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008686 ergosterol biosynthesis Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910002011 hydrophilic fumed silica Inorganic materials 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 150000001282 organosilanes Chemical class 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 238000012503 pharmacopoeial method Methods 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000005476 size effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/044—Suspensions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
Definitions
- the present invention is directed to an aerosol spray containing one or more viable bacterial species and one or more volatile siloxanes suitable for applying said one or more viable bacterial species to a surface or into the environment.
- Aerosol sprays are very useful in the application of different agents to a surface or in the environment, and it would be an interesting way of formulating live bacterial species.
- aerosol sprays comprise a watery component, which is incompatible with the formulation of live bacterial species.
- the presence of water normally also requires the presence of a preservative to prevent the growth of harmful pathogens and to control microbiological growth.
- Preservatives are harmful for the survival of co-formulated microorganisms.
- even Limited amounts of co-formulated water are sufficient to activate dormant bacteria, hereby significantly reducing the storage time for such compositions. Therefore, typical aerosol sprays are not suitable for the formulation of live bacterial species, and it was an object of the present invention to provide an aerosol composition which solves these problems of formulating and acquiring a long-term storage of live bacterial species.
- aerosol sprays comprising at least one volatile siloxane is highly useful for said purpose.
- Silicone fluids and siloxanes in particular are often used in sprays comprising crop protection products, repellants, toiletry cosmetics and other personal care products.
- Most frequently used silicone fluids are the dimethicones, the cyclomethicones and phenyltrimethicones.
- these silicone fluids are highly suitable carrier oils with a large variety of benefits such as improved slip, reduction of tack and impartation of emolliency.
- these silicone fluids have been considered to be particularly useful when they are formulated in aerosol sprays, as they tend to provide the aforementioned benefits without contributing to oiliness or greasiness.
- cyclomethicone has a relatively high volatility and does not excessively block the antiperspirant active ingredient in deodorants.
- cyclomethicones are excellent dispersing and spreading agents, are generally water white in color, low in odor, are volatile, and are resistant to chemical and oxidative degradation.
- silicone fluids are generally considered to have antimicrobial effects against a large range of (aerobic) bacteria, and have thus not been further investigated for formulating bacteria.
- silicone fluids and in particular volatile siloxanes such as cyclomethicones can be used for long-term storage of (dormant lactic acid) bacteria in aerosol sprays.
- dormant bacteria were found not to be affected by the volatile siloxanes and thus remain stable during storage. After being sprayed the dormant bacteria become active due to contact with water or vapour, and by that time, the co-formulated volatile siloxanes have evaporated and do no longer influence the survival of the activated bacteria.
- the present invention provides an aerosol spray comprising 1 -20 wt% of one or more viable probiotic bacterial strains, one or more volatile siloxanes and a propellant under pressure.
- said one or more viable bacterial species are dormant bacterial species more in particular dormant lactic acid bacteria.
- said one or more siloxanes are selected from the list comprising linear siloxanes such as dimethicones, dimethiconols, phenyltrimethicones and derivatives thereof; or cyclic siloxanes, such as cyclomethicones and derivatives thereof; more in particular cyclic siloxanes, such as cyclomethicones and derivatives thereof.
- the present invention provides an aerosol spray comprising a mixture of one or more viable (preferably dormant) bacterial species and one or more volatile siloxanes, wherein said mixture is in the form of a powder, suspension or emulsion; wherein the aerosol spray of the present invention may further comprise a propellant.
- Said propellant (under pressure) is in particular selected from the list comprising a liquefied gas more in particular one or more hydrocarbons such as methane, ethane, propane, isopropane, butane, n-butane, pentane and n-pentane; alternatively, the propellant may be a permanent compressed and/or soluble gas such as Nitrogen, Carbondioxide, Compressed air or nitrous Oxide gas.
- the aerosol spray of the present invention may further comprise an anti-sedimentation and/or anti-agglomeration agent.
- Said anti-sedimentation and/or anti- agglomeration agents are in particular selected from a list of inorganic polymers such as organoclay gels containing bentonite or hectorite; and/or fumed silica's such as aerosil.
- the aerosol spray of the present invention may further comprises one or more emollients, suspending agents, moisturizers, antioxidants, humectants, emulsifiers, viscosity modifying agents, perfumes and/or other excipients.
- the present invention provides an aerosol spray; wherein the content thereof comprises or consists of at least 50% propellant, 1 -20% siloxanes, 1 -20% lactic acid bacteria and 0.1 -10% anti-sedimentation and/or anti-agglomeration agents.
- the present invention provides an aerosol spray wherein the content thereof comprises or consists of at least 75% propellant, 5-10% cyclomethicone, 1 -10% lactic acid bacteria and 0.1 -5% bentone gel.
- the present invention provides an aerosol spray comp sing or consisting of at least 75% propellant, 5-10% cyclomethicone, 1 -10% lactic acid bacteria and 0.1 -5% aerosil.
- the aerosol spray according to the present invention is substantially free of water and preservatives.
- the present invention provides the use of an aerosol spray according to the present invention for applying said one or more viable bacterial species; specifically said viable probiotic bacterial strains to a surface or into the environment.
- the present invention provides an aerosol spray as defined herein for use in restoring and/or maintaining a healthy skin microbiota.
- the present invention thus also provides the use of an aerosol spray according to current invention for restoring and/or maintaining a healthy skin microbiota.
- Fig. 2 Stability of self-cultured (non-dried) Lac 4 & Lac 7 vs a commercial freeze dried strain of LGG, suspended (1 /10 m/m%) in silicon oil CF 6570-DM over a period of 1 year.
- This figure clearly shows that freeze drying probiotics and suspending them in an anhydrous silicon mixture is an ideal way for preventing a fast drop in viability of the viably bacteria.
- Suspending the freeze dried bacteria in a silicon mixture containing dimethicone, disiloxane and cyclopentasiloxane provides for a long term storage of this lactobacillus species.
- Fig 3 Survival curves of suspended freeze-dried L.PIantarum in different formulations (F1 -F8), whilst being stored in a pressurized canister with hydrocarbon propellants at room temperature (20 °C). After a small initial drop in viability du ng the first month, the viability remains rather constant during the following months proving that storage in a pressurized canister is a suitable method for long term survival of probiotics.
- Fig. 4 Six month stability of freeze-dried L.plantarum in different formulations versus the same formulations stored in pressurized canisters. After 6 months of storage, there is a statistical significant difference in survival for the formulations stored with propellant in a pressurized canister, than the formulations stored without propellant. The survival was better for all 8 tested formulations, proving that suspending freeze dried bacteria in a silicon oil, stored with propellant is a better method for long term stability than simply suspending the freeze dried bacteria in a silicon oil.
- Fig. 5 Stabiliy of freeze dried LAC_15 In diferent silicones and silicone mixtures after 3 months. Although small differences were noted, most were deemed insignificant.
- the present invention provides an aerosol spray comprising 1 -20 wt% of one or more viable probiotic bacterial strains, one or more volatile siloxanes and a propellant under pressure.
- the present invention provides an aerosol spray comprising a mixture of one or more viable (preferably dormant) bacterial species and one or more volatile siloxanes, wherein said mixture is in the form of a powder, suspension or emulsion.
- said one or more viable bacterial species are dormant bacterial species; more in particular dormant lactic acid bacteria.
- aerosol spray is meant to be a type of dispensing system which creates an aerosol mist.
- a can or bottle that contains the mixture of the present invention and preferably a propellant under pressure.
- the container's valve When the container's valve is opened, the mixture is forced out of the canister through the valves and emerges as an aerosol or mist.
- a large amount of propellant remains inside the can to maintain a constant pressure. Outside the can, the propellant evaporates rapidly.
- mixture is a system made up of two or more different substances which are mixed but are not combined chemically, such as a combination of volatile siloxanes and dormant bacterial species. In such mixture, the individual identities of the components are retained and they are mixed in the form of solutions, suspensions, emulsions, colloids or powders.
- powder is a dry, bulk solid composed of a large number of very fine particles that may flow freely when shaken or tilted. Powders are a special sub-class of granular materials, although the terms powder and granular are sometimes used to distinguish separate classes of material.
- the term "dormant” is meant to be a state of living/viable bacteria in which growth, development, reproduction, ... have temporarily stopped. They are in a metabollicaly dormant state in which metabolic processes are slowed down to such extent that they no longer produce significant amounts of metabolites. Many bacterial species can survive adverse conditions such as low temperature by forming (endo)spores, cysts, conidia or states of reduced metabolic activity lacking specialized cellular structures. Upon experiencing 'normal' conditions, dormant bacteria can be reactivated, such as after they come into contact with water or encountering a certain temperature or vibrations.
- the bacteria may be brought in a dormant state using art known techniques such as freeze-drying, spray-drying, vacuum drying, fluid bed drying, nitrogen cryo drying, ...
- the bacteria of the present invention are freeze-dried.
- volatile is used in relation to the disclosed siloxanes, to indicate that they have the tendency to vaporize. Volatility is directly related to a substance's vapor pressure. At a given temperature, a substance with higher vapor pressure vaporizes more readily than a substance with a lower vapor pressure. Otherwise, Substances with a lower heat of vaporization (kJ/kg) will evaporate more quickly at a given temperature than those with a higher heat of vaporization.
- the term is primarily written to be applied to liquids; however, it may be used to describe the process of sublimation which is associated with solid substances, such as dry ice (solid carbon dioxide), which can change directly from the solid state to a vapor, without becoming liquid.
- the vapor pressure of a substance is the pressure at which its gas phase is in equilibrium with its condensed phases (liquid or solid). It is a measure of the tendency of molecules and atoms to escape from a liquid or a solid.
- the vapor pressure of the volatile siloxanes of the present invention is less than 2500 kJ/kg at room temperature (25 °C), more preferably less than 1000 and even more preferably, less than 900, 800, 700, 600, 500, 400, 300, 200 kJ/kg.
- Cyclomethicones are a group of methyl siloxanes, a class of liquid silicones (cyclic polydimethylsiloxane polymers) that possess the characteristics of low viscosity and high volatilty as well as being skin emolients and in certain circumstances useful cleaning solvents.
- cyclomethicones are cyclic: both groups consist of a polymer featuring a monomer backbone of one silicon and two oxygen atoms bonded together, but instead of having a very long "linear- backbone surrounded by a series of methyl groups (which produces a clear, non-reactive, nonvolatile liquid ranging from water-thin to taffy-thick), cyclomethicones have short backbones that make closed or nearly-closed rings or "cycles" with their methyl groups, giving them many of the same properties of dimethicones but making them much more volatile.
- a more volatile siloxane such as cyclomethicone, or instead a siloxane being less volatile such as dimethicone.
- Silicones are commonly used in the personal care industry (and many others) and are perceived, upon skin contact, as being smooth, velvety, nongreasy and nontacky (Handbook of Cosmetic Science and Technology Fourth Edition 2014; New York CRC Press; 204 AD. Pg. 321 -329) . They have a low surface energy, are moisture- and temperature-resistant, biocompatible, volatile and permeable, non-toxic and non-irritating. Silicones are polymers derived from silicon (Si), carbon, oxygen and hydrogen and can be linear, cyclic or organo-functional. The most common silicone (dimethicone) has an inorganic Si-oxide backbone with organic (2x methyl) pending groups on the SI.
- a silicon polymer has a range of 2 to a few thousand monomers and has viscosity's that can range from 0.65 cSt (hexamethyldisiloxane) to + 1 million cSt cps.
- High viscosity fluids can form a protective film whilst low viscosity fluids are able to be emulsified and have better solubility with other ingredients.
- the organic groups can be modified to provide surface active properties.
- Sl-o bonds are very free to move (Si-o is 0.2kcal/mol ; c-c is 3.3 kcal/mol rotation energy), have a strong bonding energy (si-o is 1 17kcal/mol ; c-c is 85 kcal/mol bonding strength) and are flat and long (Si-o angle is 130°C, length is 0.163 nm ; c-c bond has a 1 12 0 angle and a length of 0.154 nm). This all makes for a very flexible and strong backbone.
- Polydimethylsiloxane (PDMS) also has a very low surface tension of 20 mM/m compared to ethanol (50 mM/m) and water (72 mM/m).
- PDMS polymers show a high permeability for gasses, which is linked to the solubility and diffusion coefficient (See table 2).
- Cyclic silicones are very good solvents, non- staining, colorless, odorless and have a high volatility. They are most commonly used in antiperspirant products as delivery vehicle for active ingredients. They do not feel cold on the skin due to their low heat vaporization and have a pleasant skin feel and are the suspending medium of choice for pressurized aerosol canisters. They can also prevent the formation of agglomerates at the valves because of the lubricant properties of silicones. Other suspending mediums commonly used in antiperspirants are ethanol, water and mineral oils.
- siloxanes is meant to be molecules comprising functional groups with the Si-O-Si linkage.
- the parent siloxanes include the oligomeric and polymeric hybrids with the formulae H(OSiH 2 ) affordOH and (OSiH 2 ) n .
- Siloxanes also include branched compounds, the defining feature of which is that each pair of silicon centres is separated by one oxygen atom.
- the siloxane functional group forms the backbone of silicones.
- Suitabe volatile siloxanes within the context of the present invention may be selected from the list comprising linear siloxanes such as dimethicones, dimethiconols, phenyltrimethicones and derivatives thereof; or cyclic siloxanes, such as cyclomethicones and derivatives thereof; more in particular cyclic siloxanes, such as cyclomethicones and derivatives thereof.
- the aerosol spray of the present invention may further comprise a propellant.
- propellant is meant to be a pressurized gas that is used to create movement of a fluid or powder. In particular, they are simply liquids (or gasses) that can readily be vaporized.
- Cold gas propellants may be used to fill in pressurised dispensing systems, such as aerosol sprays, to force a material through a nozzle, in aerosol spray cans, the propellant is usually a pressurized gas in equilibrium with its liquid or powder (at its saturated vapour pressure).
- Suitable propellant useful within the context of the present invention may be selected from the list comprising a liquefied gas more in particular one or more hydrocarbons such as methane, ethane, propane, isopropane, butane, n-butane, pentane and n-pentane; or a permanent compressed and/or soluble gas such as Nitrogen, Carbondioxide, Compressed air or nitrous Oxide gas.
- hydrocarbons such as methane, ethane, propane, isopropane, butane, n-butane, pentane and n-pentane
- a permanent compressed and/or soluble gas such as Nitrogen, Carbondioxide, Compressed air or nitrous Oxide gas.
- the aerosol spray of the present invention may further comprise an anti-sedimentation and/or anti-agglomeration agent.
- anti-sedimentation agent is meant to be substances which prevents particles in suspension from settling out of the fluid in which they are entrained and come to rest against a barrier, such as the bottom of the aerosol can.
- anti-agglomeration agent is meant to be substances that prevent caking or agglomeration of the components.
- Suitable anti-sedimentation and/or anti-agglomeration agents within the context of the present invention may be selected from the list comp sing inorganic polymers such as organoclay gels containing bentonite or hectorite; and/or fumed silica's such as aerosil®.
- the aerosils® can be chemically modified to obtain a better 3D structural network in the selected siloxane carrier.
- Aerosils are typically hydrophilic fumed silica's (Si02). More particulary suitable for this invention are hydrophobic silica's, usually silicas aftertreated with hydrophobic substances such as, but not limited to,: Dimethyldichlorislane, polydimethyliloxane, organosilane, hexadecylsilane, octamethylcyclotetrasiloxane, methacrylsilane, silicone oil, aminosilane and derivates thereof.
- hydrophobic silica's usually silicas aftertreated with hydrophobic substances such as, but not limited to,: Dimethyldichlorislane, polydimethyliloxane, organosilane, hexadecylsilane, octamethylcyclotetrasiloxane, methacrylsilane, silicone oil, aminosilane and derivates thereof.
- the aerosol spray of the present invention may contain any further substances which may be useful in the context of the present invention.
- futher substances include but are not limited to one or more emollients, moisturizers, antioxidants, humectants, suspending agents, emulsifiers, viscosity modifying agents, polarity modifying agents, perfumes, electrolytes, color modifying agents and other excipients.
- Suitable antioxidants might be, but are not limited to: BHT, BHA, propyl gallate, ascorbic acid & Sodium- metabisulfiet.
- Suitable viscosity modifying agents might be, but are not limited to, different colloids, silicone resins, propyleneglycol, organogels, aerosils, ...
- a suitable additional component in the aerosol sprays of the present invention is for example Tegosoft ®, i.e. polypropylene glycol butyl ether or ppg-14-butylether.
- Tegosoft ® is a light cosmetic oil with very good spreading properties which is often used as an emollient in skin care products such as creams, lotions, bath oils, .... It also has excellent suspending properties for active ingredients in aerosol formulations.
- PPG-Butyl Ether ingredients in cosmetic formulations enhance the appearance of dry or damaged skin by reducing flaking and restoring suppleness.
- the present invention provides an aerosol spray of which the content comprises or consists of at least 10% propellant, 10-40% siloxanes, 10-40% lactic acid bacteria, 0-5% anti-sedimentation and/or anti-agglomeration agents and 0-5% of other additives.
- the present invention provides an aerosol spray of which the content comprises or consists at least 50% propellant, 1 -20 % siloxanes, 1 -20 % lactic acid bacteria, 0.1 -5% anti-sedimentation and/or anti-agglomeration agents and 0-5% of other additives.
- the aerosol sprays of the present invention contain from 1 -20% of lactic acid bacteria; more in particular from 1 -10%; even more in particular about 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1 % of lactic acid bacteria.
- the aerosol sprays of the present invention preferably contain a low amount of anti- sedimentation agents such as less than 5%, less than 4%, less than 3%, less than 2%, less than 1 % or even no anti-sedimentation and/or anti-agglomeration agent if feasible.
- the present invention provides an aerosol spray of which the content comprises or consists of at least 75% propellant, 5-10% siloxanes, 1 -10% lactic acid bacteria and 0-5% anti-sedimentation and/or anti-agglomeration agents.
- the present invention provides an aerosol spray of which the content comprises or consists of at least 80% propellant, 1 -8% siloxanes, 1 -8% lactic acid bacteria and 0-4% anti-sedimentation and/or anti-agglomeration agents.
- the present invention provides an aerosol spray of which the content comprises or consists of at least 90% propellant, 1 -4% siloxanes, 1 -4% lactic acid bacteria and 0-2% anti-sedimentation and/or anti-agglomeration agents.
- the anti-sedimentation and/or anti-agglomeration agent is selected from bentone gel and aerosil®.
- the present invention provides an aerosol spray of which the content comprises or consists of at least 75% propellant, 5-10% cyclomethicone, 1 -10% lactic acid bacteria and 0-5% bentone gel.
- the present invention provides an aerosol spray of which the content comprises or consists of at least 75% propellant, 5-10% cyclomethicone, 1 - 10% lactic acid bacteria and 0-5% aerosil.
- the aerosol spray according to the present invention is substantially free of water and preservatives.
- the term "substantially free” is meant to be less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, preferably less than 1 %.
- the compartment containing the bacteria is preferably substantially free of water and preservatives.
- the present invention provides the use of an aerosol spray according to the present invention for applying said one or more live bacterial species to a surface or into the environment.
- surface should be interpreted in its broadest sense, i.e. it may include surfaces of an object, however, it may also include the skin of humans or animals.
- aerosol sprays of the present invention may also be topical aerosol sprays, wherein the term "topical” is meant to be the local delivery at a specified location of the body, in particular the application to a particular place on or in the body. In particular, it includes the application to mucous membranes via aerosols.
- the present invention provides an aerosol spray as defined herein for use in restoring and/or maintaining a healthy skin microbiota.
- the present invention thus also provides the use of an aerosol spray according to the current invention for restoring and/or maintaining a healthy skin microbiota.
- Athlete's foot and other dermal mycotic infections are currently treated with antimycotics such as miconazole that interferes with the ergosterol synthesis.
- a well-known commercial product containing miconazole is daktarin® spray, preferred for its ease of use.
- Both antibiotics & antimycotics know an increasing trend in resistance. Therefore, alternative treatments such as the use of probiotics for topical diseases, would be beneficial for patients.
- Most probiotics exert beneficial effects for the host (human) by preventing the invasion & colonization of pathogens.
- Some probiotics like lactobacillus species, are able to combat those pathogens by excreting organic acids, hydrogen peroxide & antimicrobiological peptides into the environment.
- LGG Self-cultured LGG (i.e. Iac7 or LGG)
- Lac 4 & Lac 7 were cultured in liquid MRS (de MAN, Rogosa & Sharpe-Carl Roth) medium (37 °C) until fully grown. The medium was centrifuged for 10 minutes at 2780 G. The supernatant was disposed and the bacterial pellet was further used.
- MRS de MAN, Rogosa & Sharpe-Carl Roth
- the sealed bags were opened at certain time points for stability testing.
- the falcon tube containing 1 gram of anhydrous substance was further processed by adding 1 gram of an emulsifier mixture (consisting of polysorbate 80 & sorbitansesquioleate) and 8 gram of physiological water. This formed an emulsion through which the bacteria could get into contact with water and were reactivated. Further sample preparation and plate counting happened as described above and was derived from pharmacopeia (8.0) method 2.6.12: Microbiological examination of non-sterile products: microbial enumeration tests and 2.6.13: microbiological examination of non-sterile products: test for specified micro-organisms.
- a freeze dried strain of L.PIantarum (THT®-Freeze dried with maltodextrine) was sieved to obtain a powder fraction with a particle size ⁇ 50 micron, to ease passing of the valve and nozzle and to prvent blockage.
- the bacteria were suspended in Mirasil CM5® (decamethylcyclopentasiloxane), a volatile cyclomethicone and/or Tegosoft PBE® (propoxylated alcohol -ppg 14 butylether), both acting as suspending media.
- An organoclay component bentone gel vs5 PC V® (cyclopentasiloxane, disteardimonium hectorite & propylene carbonate), was used as anti-sedimentation and anti-agglomeration agent.
- a total of 8 formulations (concentrates) were prepared in different concentrations (see table 3), before filling with propellant in the aerosol canisters.
- compositions of the different formulations The concentrate is filled in canisters (20%) after which 80% propellant is added, making a 5-fold dilution of the concentrate.
- a sieve fraction ⁇ 30 micron was used for sample 6, as opposed to all the other formulation samples that have a powder fraction ⁇ 50 micron.
- the canisters were evaluated for viability of the bacteria as well as for the spray characteristics and residue & sedimentation properties of the suspended powder. Too much sedimentation can result in caking and consequently failure of product release or may lead to frequent nozzle blockages.
- the canisters are filled with 20% formulation and 80 % propellant.
- the propellant used is a mixture of LPG (Propane/Butane/lsobutane - 29/69/2) & Butane (55/45). Under pressure ( ⁇ 2-4 bar), it is present as a liquefied propellant.
- CFU determination of the formulations was performed by adding 1 gram of emulsifier mixture (70% tween 80/ 30% span 83) and 8 gram of physiological water, shaken until dissolved, followed by a 10-fold serial dilution.
- Plating was performed according to the "Copacabana method” (Spread plating with glass beads) followed by CFU counting after 3 days of incubation at 37 °C. All materials and liquids used were sterilized through autoclaving.
- CFU determination of the aerosol canisters was performed by spraying 5 grams from the canister and waiting ( ⁇ 1 hour) until all the propellant had evaporated. Consequently 1 gram of formulation remained in the recipient. Further sample preparation was performed as described above.
- the survival curves of L. Plantarum in the filled canisters show an average 1 -log decrease after 1 month of storage stability (Fig. 3). This indicates a small drop in viability right after or during the filling of the canisters.
- the propellant gas is kept under its partial pressure ( ⁇ 4 bar) before filling. Under a slight overpressure, the liquid is filled in the canister where it mixes with the present formulation, thus the present bacteria experience a pressure shock.
- Another explanation might be that during the use of the canister, by opening the valve nozzle, aerosol formation is paired with high shear forces to eject the bacterial powder from the canister.
- the viability in the filled canisters remains rather interestingly constant, with a maximal drop of 0.5-1 Log in viability.
- the viability decreased with a couple of logs more for some formulations.
- the start-to-end (6 month) viability-drop was a 1 -log reduction for F3, a 2-log reduction for F4 and F5, a 3-log reduction for F8, F1 and F7; and a 5- log reduction for the F6 and F2 canister.
- the formulations preferably contain no or only a low amount of anti-sedimentation agents such as bentone gel.
- the viability in F1 (50 m) is significantly (2-log) higher than F6 (30 pm), indicating that a smaller particle size is worse for the survival.
- the formulations of the present invention preferably have a particle size larger then 30 micron.
- Figure 4 shows a comparison of the different formulations as such or under pressure in the filled canisters.
- the goal of this example was to obtain a screening platform wherein the influence of different silicones and silicone-mixtures was evaluated on the viability of freeze dried L. Plantarum. Comparisons were made for cyclic vs linear silicone molecules. Also the chain length (# siloxane molecules ⁇ Viscosity) was taken into comparison as smaller molecules might penetrate the cell more, disturbing metabolic processes once active again. Finally, the hypothesis that a mixture of silicones might cancel out the negative effects of different individual silicones, unless the negative effects are cumulative, was evaluated. These extensive comparative stability studies allow us to formulate a more stable aerosol formulation containing freeze dried Lactobacillus species, suspended in silicon oils for topical use.
- freeze dried L.plantarum powder was suspended 1/25 (m/m %) in different silicones or silicone mixtures (see table 4), commonly used in antiperspirants. Table 4. Different silicone compositions wherein freeze dried L. Plantarum is suspended 1 /25
- the higher viscosity silicone CF 6570 was used as reference silicone as this mixture was previously used in the stability study of example 1 .
- Different fractions of 1 gram were weighed in falcon tubes and stored in laminated aluminum pouches (Daklapack®- PET/ALU/NY/LDPE) to protect from light, oxygen and relative humidity and stored at room temperature (20 °C).
- a TO determination of the powder was performed before making the suspensions and resulted in (5.85 ⁇ 0.71 ) E+1 1 CFU/gram. Further sampling was performed after 1 week, 2 weeks, 1 , 3 and 6 months. During sampling, 3 falcon tubes of the same sample were taken and plates were counted in triplicate as described in 2.1 . Blanc samples (reference) were stored as 100 mg powder (not-suspended).
- the single silicone components are shown on the left-hand side of fig 5 and the more complex mixtures (3-5 components) are on the right-hand side.
- the silicone mixtures on the right-hand side of fig 5 show a better survival compared to the single silicones on the left, indicating that a mixture of different components (partially) cancels out some negative effect observed for the single component silicones.
- Tegosoft ® ppg-14 butylether
- ppg-14 butylether is a biodegradable and moderately volatile propylene glycol n- butyl ether commonly found in antiperspirants. It has no negative influence on the stability of freeze dried bacte a in a pressurized aerosol canister compared to cyclopentasiloxane (Fig 3- 4).
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL265988A IL265988B2 (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing viable bacterial species |
EP17803795.8A EP3532170B1 (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing viable bacterial species |
CN201780066976.0A CN110248638A (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing bacterial species living |
PL17803795T PL3532170T3 (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing viable bacterial species |
CA3041201A CA3041201A1 (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing viable bacterial species |
HRP20220247TT HRP20220247T1 (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing viable bacterial species |
JP2019522242A JP2019534280A (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing live bacterial species |
BR112019008225-5A BR112019008225B1 (en) | 2016-10-28 | 2017-10-27 | AEROSOL SPRAY CONTAINING VIABLE BACTERIAL SPECIES AND ITS USE |
EA201991053A EA038061B1 (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing viable lactic acid bacterial strains |
RS20220177A RS62950B1 (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing viable bacterial species |
MX2019004917A MX2019004917A (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing viable bacterial species. |
KR1020197014866A KR102554682B1 (en) | 2016-10-28 | 2017-10-27 | Aerosol sprays containing live bacterial species |
LTEPPCT/EP2017/077547T LT3532170T (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing viable bacterial species |
ES17803795T ES2907586T3 (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing viable bacterial species |
DK17803795.8T DK3532170T3 (en) | 2016-10-28 | 2017-10-27 | AEROSOLSPRAY CONTAINING VIVABLE BACTERIAL SPECIES |
US16/344,630 US20200179464A1 (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing viable bacterial species |
AU2017350502A AU2017350502B2 (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing viable bacterial species |
SI201731090T SI3532170T1 (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing viable bacterial species |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE2016/5812A BE1024189B1 (en) | 2016-10-28 | 2016-10-28 | SPRAYER WITH BACTERIAL SPECIES |
BE2016/5812 | 2016-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018078067A1 true WO2018078067A1 (en) | 2018-05-03 |
Family
ID=58046399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/077547 WO2018078067A1 (en) | 2016-10-28 | 2017-10-27 | Aerosol spray containing viable bacterial species |
Country Status (21)
Country | Link |
---|---|
US (1) | US20200179464A1 (en) |
EP (1) | EP3532170B1 (en) |
JP (1) | JP2019534280A (en) |
KR (1) | KR102554682B1 (en) |
CN (1) | CN110248638A (en) |
AU (1) | AU2017350502B2 (en) |
BE (1) | BE1024189B1 (en) |
BR (1) | BR112019008225B1 (en) |
CA (1) | CA3041201A1 (en) |
DK (1) | DK3532170T3 (en) |
EA (1) | EA038061B1 (en) |
ES (1) | ES2907586T3 (en) |
HR (1) | HRP20220247T1 (en) |
IL (1) | IL265988B2 (en) |
LT (1) | LT3532170T (en) |
MX (1) | MX2019004917A (en) |
PL (1) | PL3532170T3 (en) |
PT (1) | PT3532170T (en) |
RS (1) | RS62950B1 (en) |
SI (1) | SI3532170T1 (en) |
WO (1) | WO2018078067A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020234035A1 (en) * | 2019-05-20 | 2020-11-26 | Evonik Operations Gmbh | Use of polyglycerol esters als as carriers for microbiological active ingredients |
EP3871653A1 (en) * | 2020-02-27 | 2021-09-01 | MicroCen Trans s.r.o | A composition containing a vital probiotic culture for human or veterinary use as a deodorant |
BE1029676B1 (en) * | 2021-08-12 | 2023-03-13 | Yun | SPRAYABLE FORMULATION CONTAINING LIVE AND/OR STABLE BACTERIA |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019201777A1 (en) * | 2018-04-19 | 2019-10-24 | Evonik Degussa Gmbh | Biocompatible siloxanes for formulation of microorganisms |
KR102270560B1 (en) * | 2019-10-10 | 2021-06-29 | 연세대학교 산학협력단 | Electrostatic precipitator and organism damage prevention system that can occur during bio-aerosol capture using the same |
KR102467827B1 (en) * | 2020-08-31 | 2022-11-16 | 연세대학교 산학협력단 | Method for prevent damage that occurs during the microbial aerosolization process |
KR102314957B1 (en) * | 2021-01-22 | 2021-10-19 | 연세대학교 산학협력단 | Apparatus for monitoring bio-particles in air |
WO2023223327A1 (en) * | 2022-05-17 | 2023-11-23 | Ecological Balancing Technologies Corporation | Air purifier for internal spaces |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050196480A1 (en) * | 2004-03-04 | 2005-09-08 | Michael Sullivan | Skin treatment method with lactobacillus extract |
US20120328586A1 (en) * | 2005-06-22 | 2012-12-27 | Organobalance Gmbh | Methods and means for protecting the skin against pathogenic microorganisms |
US20160008412A1 (en) * | 2011-05-03 | 2016-01-14 | Dupont Nutrition Biosciences Aps | Probiotic bacteria for the topical treatment of skin disorders |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6645506B1 (en) * | 1997-04-18 | 2003-11-11 | Ganeden Biotech, Inc. | Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil |
US20050238632A1 (en) * | 2004-04-23 | 2005-10-27 | Alburty David S | Propellant formulations |
PL1909916T3 (en) * | 2005-07-30 | 2009-10-30 | Unilever Nv | Anhydrous spray compositions containing a particulate antiperspirant active and a moisturising agent |
US20080107699A1 (en) * | 2006-10-25 | 2008-05-08 | Mark Spigelman | Method of using topical probiotics for the inhibition of surface contamination by a pathogenic microorganism and composition therefor |
EP2394640A1 (en) * | 2010-05-21 | 2011-12-14 | MediGene AG | Improved liposomal formulations of lipophilic compounds |
ES2674328T3 (en) * | 2011-05-06 | 2018-06-28 | Belano Medical Ag | New lactic acid bacteria and compositions containing them |
CN104887715B (en) * | 2015-06-19 | 2016-08-17 | 哈高科白天鹅药业集团有限公司 | A kind of Bacillus Subtilis Spray |
-
2016
- 2016-10-28 BE BE2016/5812A patent/BE1024189B1/en active IP Right Grant
-
2017
- 2017-10-27 IL IL265988A patent/IL265988B2/en unknown
- 2017-10-27 WO PCT/EP2017/077547 patent/WO2018078067A1/en unknown
- 2017-10-27 PL PL17803795T patent/PL3532170T3/en unknown
- 2017-10-27 PT PT178037958T patent/PT3532170T/en unknown
- 2017-10-27 AU AU2017350502A patent/AU2017350502B2/en active Active
- 2017-10-27 LT LTEPPCT/EP2017/077547T patent/LT3532170T/en unknown
- 2017-10-27 KR KR1020197014866A patent/KR102554682B1/en active IP Right Grant
- 2017-10-27 CN CN201780066976.0A patent/CN110248638A/en active Pending
- 2017-10-27 CA CA3041201A patent/CA3041201A1/en active Pending
- 2017-10-27 RS RS20220177A patent/RS62950B1/en unknown
- 2017-10-27 SI SI201731090T patent/SI3532170T1/en unknown
- 2017-10-27 DK DK17803795.8T patent/DK3532170T3/en active
- 2017-10-27 HR HRP20220247TT patent/HRP20220247T1/en unknown
- 2017-10-27 EA EA201991053A patent/EA038061B1/en unknown
- 2017-10-27 MX MX2019004917A patent/MX2019004917A/en unknown
- 2017-10-27 EP EP17803795.8A patent/EP3532170B1/en active Active
- 2017-10-27 BR BR112019008225-5A patent/BR112019008225B1/en active IP Right Grant
- 2017-10-27 US US16/344,630 patent/US20200179464A1/en active Pending
- 2017-10-27 JP JP2019522242A patent/JP2019534280A/en active Pending
- 2017-10-27 ES ES17803795T patent/ES2907586T3/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050196480A1 (en) * | 2004-03-04 | 2005-09-08 | Michael Sullivan | Skin treatment method with lactobacillus extract |
US20120328586A1 (en) * | 2005-06-22 | 2012-12-27 | Organobalance Gmbh | Methods and means for protecting the skin against pathogenic microorganisms |
US20160008412A1 (en) * | 2011-05-03 | 2016-01-14 | Dupont Nutrition Biosciences Aps | Probiotic bacteria for the topical treatment of skin disorders |
Non-Patent Citations (7)
Title |
---|
"Handbook of Cosmetic Science and Technology, 4th ed.", vol. 204 AD, 2014, CRC PRESS, pages: 321 - 329 |
ARAKATSU S: "Nyusankin o Riyoshita Kinosei Keshohin Shokuhin no Kaihatsu Kenkyu Doko /THE DEVELOPMENT OF FUNCTIONAL COSMETICS AND FOOD USING LACTIC ACID BACTERIA", SHOKUHIN-SHOKUHIN-TENKABUTSU-KENKYUSHI = FOODS & FOOD INGREDIENTS JOURNAL OF JAPAN, FFI JANARU HENSHU IINKAI, TOYONAKA, JP, vol. 209, no. 9, 1 January 2004 (2004-01-01), pages 780 - 792, XP003007238, ISSN: 0919-9772 * |
DANIEL BONNER: "Introduction to Aerosols SATA Aerosol 101 CONTENT", 18 March 2015 (2015-03-18), XP055435894, Retrieved from the Internet <URL:https://southernaerosol.com/wp-content/uploads/2015/06/7-A101-Propellants-Use-Safety.pdf> * |
DATABASE GNPD [online] MINTEL; 1 December 2008 (2008-12-01), "Moisture Milk", XP002776772, Database accession no. 1033516 * |
DATABASE GNPD [online] MINTEL; 1 December 2010 (2010-12-01), "Milk fresh", XP002776773, Database accession no. 1460102 * |
J SCHREZENMEIR: "Probiotics, prebiotics, and synbiotics-approaching a definition", AM J CLIN NUTR 2001;73(SUPPL), 31 December 2001 (2001-12-31), pages 361S - 364S, XP055364468, Retrieved from the Internet <URL:http://ajcn.nutrition.org/content/73/2/361s.full.pdf> [retrieved on 20170412] * |
MORGAN ET AL.: "Preservation of micro-organisms by drying; a review", JOURNAL OF MICROBIOLOGICAL METHODS, vol. 66, 2006, pages 183 - 193, XP025073180, DOI: doi:10.1016/j.mimet.2006.02.017 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020234035A1 (en) * | 2019-05-20 | 2020-11-26 | Evonik Operations Gmbh | Use of polyglycerol esters als as carriers for microbiological active ingredients |
EP3871653A1 (en) * | 2020-02-27 | 2021-09-01 | MicroCen Trans s.r.o | A composition containing a vital probiotic culture for human or veterinary use as a deodorant |
BE1029676B1 (en) * | 2021-08-12 | 2023-03-13 | Yun | SPRAYABLE FORMULATION CONTAINING LIVE AND/OR STABLE BACTERIA |
WO2023017141A3 (en) * | 2021-08-12 | 2023-04-20 | Yun NV | Sprayable formulation comprising viable and/or stable bacteria |
Also Published As
Publication number | Publication date |
---|---|
CN110248638A (en) | 2019-09-17 |
MX2019004917A (en) | 2019-08-29 |
RS62950B1 (en) | 2022-03-31 |
EA201991053A1 (en) | 2019-09-30 |
JP2019534280A (en) | 2019-11-28 |
KR20190099198A (en) | 2019-08-26 |
BR112019008225A2 (en) | 2019-07-09 |
AU2017350502B2 (en) | 2022-12-01 |
CA3041201A1 (en) | 2018-05-03 |
HRP20220247T1 (en) | 2022-07-08 |
DK3532170T3 (en) | 2022-03-07 |
EP3532170B1 (en) | 2021-11-24 |
EP3532170A1 (en) | 2019-09-04 |
PT3532170T (en) | 2022-02-28 |
IL265988A (en) | 2019-06-30 |
LT3532170T (en) | 2022-03-25 |
KR102554682B1 (en) | 2023-07-12 |
EA038061B1 (en) | 2021-06-30 |
BR112019008225B1 (en) | 2022-11-16 |
PL3532170T3 (en) | 2022-03-21 |
BE1024189B1 (en) | 2017-12-05 |
US20200179464A1 (en) | 2020-06-11 |
IL265988B1 (en) | 2023-09-01 |
SI3532170T1 (en) | 2022-07-29 |
ES2907586T3 (en) | 2022-04-25 |
IL265988B2 (en) | 2024-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017350502B2 (en) | Aerosol spray containing viable bacterial species | |
EP2581431B1 (en) | Aerosol composition | |
JP6282849B2 (en) | Emulsion type aerosol composition | |
EP2895142B1 (en) | Aerosol antiperspirant compositions, products and methods | |
US20120189557A1 (en) | Topical Delivery with a Carrier Fluid | |
US20220062354A1 (en) | Topical formulations for the delivery of microbially derived materials | |
AU2018452265B2 (en) | Personal care compositions | |
JP2015024973A (en) | Aerosol-type foam-like sunburn inhibitor | |
JP6018438B2 (en) | Dripping aerosol products | |
EP3104871B1 (en) | Topical composition comprising an antibacterial agent | |
JP6214135B2 (en) | Pest repellent aerosol agent for human body, and pest repellent and cooling method using the same. | |
JP4566067B2 (en) | Powder cosmetics | |
JP2013112798A (en) | Emulsion aerosol composition | |
AU2019333309B2 (en) | Cryogenic, kinetically active formulations and systems for their dispensing | |
EP3116466B1 (en) | Aerosol antiperspirant compositions, products and methods | |
JP2013241358A (en) | Powder containing aerosol composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17803795 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3041201 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2019522242 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019008225 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20197014866 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017350502 Country of ref document: AU Date of ref document: 20171027 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017803795 Country of ref document: EP Effective date: 20190528 |
|
ENP | Entry into the national phase |
Ref document number: 112019008225 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190424 |